Related references
Note: Only part of the references are listed.Coccidioidomycosis in selected immunosuppressed hosts
Janis E. Blair et al.
MEDICAL MYCOLOGY (2019)
A review of innate and adaptive immunity to coccidioidomycosis
Chiung-Yu Hung et al.
MEDICAL MYCOLOGY (2019)
Infectious complications in patients on treatment with Ruxolitinib: case report and review of the literature
Maria Veronica Dioverti et al.
INFECTIOUS DISEASES (2018)
Ruxolitinib-associated infections: A systematic review and meta-analysis
Federico Lussana et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Risks of Ruxolitinib in STAT1 Gain-of-Function-Associated Severe Fungal Disease
Ofer Zimmerman et al.
OPEN FORUM INFECTIOUS DISEASES (2017)
2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Treatment of Coccidioidomycosis
John N. Galgiani et al.
CLINICAL INFECTIOUS DISEASES (2016)
Universal Fungal Prophylaxis and Risk of Coccidioidomycosis in Liver Transplant Recipients Living in an Endemic Area
Allon Kahn et al.
LIVER TRANSPLANTATION (2015)
The Effect of CYP3A4 Inhibition or Induction on the Pharmacokinetics and Pharmacodynamics of Orally Administered Ruxolitinib (INCB018424 Phosphate) in Healthy Volunteers
Jack G. Shi et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Share Paper
